Long-term observation of therapy and outcome in acquired hemophilia A

Long-term observation of therapy and outcome in acquired hemophilia A - AHA_IIT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023915

Enrollment

150

Registered

2021-03-30

Start date

2021-10-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D68.31

Interventions

Group 1: Patients with acquired hemophilia A will be asked for co-morbidities post AHA-therapy in a telephone interview.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with approved AHA-diagnosis

Exclusion criteria

Exclusion criteria: Patients under 18 years Patients without AHA-diagnosis

Design outcomes

Primary

Measure	Time frame
Laboratory values: FVIII activity (before and during therapy, maximum); inhibitor titer against hFVIII (before and (if available) during therapy); hemoglobin (Hb); aPTT ; vWF-Ag; vWF-RCo (vWF-risocetin cofactor); Lupus anticoagulans ; thrombocyte count Clinical course: Time from admission to AHA-diagnosis [days]; place/institution of first presentation (generals practitioner, emergency room, …); bleeding events (localisation, type, severity); cause of AHA (idiopathic, malignant disease, pregnancy, other autoimmune disease) Therapy: Bypassing Agents (aPCC, rFVIIa); pFVIII (Hyate:C, Obizur: initial dose, following dose/frequency); Obizur: anti-rpFVIII (U/ml) if measured; IST (immunosupressive therapy: corticosteroides, combination of cyclophosphamide, rituximab, others); other medication; prophylaxis(e.g. short time prophylaxis with aPCC); supportive blood transfusion (type, number) Interventions/sugery/procedures during AHA Outcome (complete remission, adverse events during therapy (thromboembolic events?))	—

Measure

Time frame

Laboratory values: FVIII activity (before and during therapy, maximum); inhibitor titer against hFVIII (before and (if available) during therapy); hemoglobin (Hb); aPTT ; vWF-Ag; vWF-RCo (vWF-risocetin cofactor); Lupus anticoagulans ; thrombocyte count Clinical course: Time from admission to AHA-diagnosis [days]; place/institution of first presentation (generals practitioner, emergency room, …); bleeding events (localisation, type, severity); cause of AHA (idiopathic, malignant disease, pregnancy, other autoimmune disease) Therapy: Bypassing Agents (aPCC, rFVIIa); pFVIII (Hyate:C, Obizur: initial dose, following dose/frequency); Obizur: anti-rpFVIII (U/ml) if measured; IST (immunosupressive therapy: corticosteroides, combination of cyclophosphamide, rituximab, others); other medication; prophylaxis(e.g. short time prophylaxis with aPCC); supportive blood transfusion (type, number) Interventions/sugery/procedures during AHA Outcome (complete remission, adverse events during therapy (thromboembolic events?))

—

Secondary

Measure	Time frame
Current age or if passed away in the meantime reached age with year and cause of death (if available); age at initial diagnosis of AHA; gender/sex; co-morbidities before AHA-diagnosis; medical history (NSTEMI, mamma-Ca; thrombosis; surgeries; previous pregnancies, ...)	—

Countries

Germany

Contacts

Public ContactWolfgang Miesbach

Hämophiliezentrum, Institut für Transfusionsmedizin, Medizinische Klinik III, Goethe Universitätsklinikum

wolfgang.miesbach@kgu.de06963015051

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026